Skip to main content
SpringerLink
Log in

What constitutes failure of H. pylori eradication therapy?

  • Chapter
Book cover Helicobactor pylori

  • 152 Accesses

Abstract

Helicobacter pylori eradication marks a historical milestone in the cure of peptic ulcer disease and indications for other H. pylori-associated clinical conditions are now expanding and include also the possible prevention of gastric cancer in selected populations at risk1,2. H. pylori eradication therapies are still complex, and the increased use of these treatments therefore demands careful consideration of factors responsible for treatment failure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Malfertheiner P, Mégraud F, O’Morain C et al. for the European Helicobacter pylori Study Group (EHPSG): Current European concepts in the management of Helicobacter pylori infection — the Maastricht Consensus Report. Eur J. Gastroenterol Hepatol. 1997; 9: 1–2.

    Article  PubMed  CAS  Google Scholar 

  2. Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection — the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16: 167–80

    Article  PubMed  CAS  Google Scholar 

  3. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, El Zimaity HM. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther. 2000; 14: 211–15.

    Article  PubMed  CAS  Google Scholar 

  4. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl. 1993; 196: 34–7.

    Article  PubMed  CAS  Google Scholar 

  5. de Boer WA, Tytgat GN. How to treat Helicobacter pylori infection — should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint. Eur J Gastroenterol Hepatol. 1996; 8: 709–16.

    PubMed  Google Scholar 

  6. Lind T, Megraud F, Unge P et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology. 1999; 116: 248–53.

    Article  PubMed  CAS  Google Scholar 

  7. Misiewicz LT, Harris AW, Bardhan KD et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut. 1997; 41: 735–9.

    Article  PubMed  CAS  Google Scholar 

  8. Stevens VJ, Shneidman RJ, Johnson RE, Boles M, Steele PE, Lee NL. Helicobacter pylori eradication in dyspeptic primary care patients: a randomized controlled trial of a pharmacy intervention. West J Med. 2002; 176: 92–6.

    PubMed  Google Scholar 

  9. Monica PD, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther. 2002; 16: 1269–75.

    Article  PubMed  Google Scholar 

  10. Khan Z, Nair P, O’Shea C, Spiers N, Playford RJ, Wicks AC. Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study. Scand J Gastroenterol. 2002; 37: 144–7.

    Article  PubMed  CAS  Google Scholar 

  11. Treiber G. Treating H. pylori shorter than one week–a real future perspective? Z Gastroenterol. 2000; 38: 807–12.

    Article  PubMed  CAS  Google Scholar 

  12. van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol. 1999; 94: 1751–9.

    Article  PubMed  Google Scholar 

  13. Osato MS, Reddy SG, Piergies AA, Bochenek WJ, Testa RT, Graham DY. Comparative efficacy of new investigational agents against Helicobacter pylori. Aliment Pharmacol Ther. 2001; 15: 487–92.

    Article  PubMed  CAS  Google Scholar 

  14. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol. 1999; 94: 725–9.

    Article  PubMed  CAS  Google Scholar 

  15. Bazzoli F, Zagari M, Pozzato P et al. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 1998; 12: 439–45.

    Article  PubMed  CAS  Google Scholar 

  16. Chiba N. Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens. Can J Gastroenterol. 2000; 14: 885–9.

    PubMed  CAS  Google Scholar 

  17. Goddard AF, Jessa MJ, Barrett DA et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology. 1996; 111: 358–67.

    Article  PubMed  CAS  Google Scholar 

  18. Goddard AF. Review article: Factors influencing antibiotic transfer across the gastric mucosa. Aliment Pharmacol Ther. 1998; 12: 1175–84.

    Article  PubMed  CAS  Google Scholar 

  19. de Boer WA, Borody TJ. Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy. Dig Liver Dis. 2000; 32: 673–5.

    Article  PubMed  Google Scholar 

  20. Peitz U, Sulliga M, Wolle K et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther. 2002; 16: 315–24.

    Article  PubMed  CAS  Google Scholar 

  21. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori Gastroenterology. 1998; 115: 1278–82.

    CAS  Google Scholar 

  22. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001; 20: 820–823.

    Article  PubMed  CAS  Google Scholar 

  23. Meyer JM, Silliman NP, Wang W et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002; 136: 13–24.

    Article  PubMed  Google Scholar 

  24. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med. 2001; 161: 1217–20.

    Article  PubMed  CAS  Google Scholar 

  25. Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol. 2002; 51: 705–9.

    PubMed  CAS  Google Scholar 

  26. Cabrita J, Oleastro M, Matos R et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990–1999). J Antimicrob Chemother. 2000; 46: 1029–31.

    Article  PubMed  CAS  Google Scholar 

  27. Houben MH, Van Der BD, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy–the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999; 13: 1047–55.

    Article  PubMed  CAS  Google Scholar 

  28. Heep M, Lehn N, Brandstatter B, Rieger U, Senzenberger S, Wehrl W. Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2002; 21: 143–5.

    Article  PubMed  CAS  Google Scholar 

  29. Gisbert JP, Pajares JM. Helicobacter pylori `rescue’ regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002; 16: 1047–57.

    Article  PubMed  CAS  Google Scholar 

  30. Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection–the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16: 167–80.

    Article  PubMed  CAS  Google Scholar 

  31. de Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. Br Med J. 2000; 320: 31–4.

    Article  Google Scholar 

  32. Dore MP, Piana A, Carta M et al. Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1998; 12: 635–9.

    Article  PubMed  CAS  Google Scholar 

  33. Dore MP, Kwon DH, Sepulveda AR, Graham DY, Realdi G. Stable amoxicillin resistance in Helicobacter pylori. Helicobacter. 2001; 6: 79.

    Article  PubMed  CAS  Google Scholar 

  34. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter. 2002; 7: 225–31.

    Article  PubMed  CAS  Google Scholar 

  35. Wong WM, Wong BC, Lu H et al. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther. 2002; 16: 793–98.

    Article  PubMed  CAS  Google Scholar 

  36. Ellenrieder V, Boeck W, Richter C, Marre R, Adler G, Glasbrenner B. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol. 1999; 34: 750–6.

    Article  PubMed  CAS  Google Scholar 

  37. Miehlke S, Kirsch C, Ochsenktihn T et al. High-dose omeprazole/amoxicillin therapy versus quadruple therapy for treatment of Helicobacter pylori resistant against both metronidazole and clarithromycin - a prospective, randomized cross-over study. Gastroenterology. 2001; 120(5 Suppl. 1]:Al20.

    Google Scholar 

  38. Di Caro S, Ojetti V, Zocco MA et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002; 16: 527–32.

    Article  PubMed  Google Scholar 

  39. Perri F, Festa V, Clemente R et al. Randomized study of two `rescue’ therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 2001; 96: 58–62.

    PubMed  CAS  Google Scholar 

  40. Spechler S, Fischbach L, Feldman M. Clinical aspects of genetic variability in Helicobacter pylori. J Am Med Assoc. 2000; 283: 1264–6.

    Article  CAS  Google Scholar 

  41. El-Omar EM, Chow WH, Rabkin CS. Gastric cancer and H. pylori: host genetics open the way. Gastroenterology. 2001; 121: 1002–13.

    Article  PubMed  CAS  Google Scholar 

  42. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol. 1994; 29: 425–9.

    Article  PubMed  CAS  Google Scholar 

  43. Yamaoka Y, Kodama T, Kita M, et al. Relation between clinical presentation, Helicobacter pylori density, interleukin 1 beta and 8 production, and cagA status. Gut. 1999; 45: 804–11.

    Article  PubMed  CAS  Google Scholar 

  44. Treiber G. The influence of drug dosage on Helicobacter pylori eradication. A cost-effectiveness analysis. Am J Gastroenterol. 1996; 91: 246–57.

    PubMed  CAS  Google Scholar 

  45. Treiber G, vanDoorn LJ, Rudi J et al. The importance of the pretherapeutic cag-A status for the success of Helicobacter pylori eradication therapy. Gastroenterology. 2001; 120 (Suppl. 1): A582 (abstract).

    Google Scholar 

  46. Van der Hulst RW, van der Ende A, Dekker FW et al. Effect of Helicobacter pylori eradication on gastritis in relation to cag-A: a prospective 1-year follow-up study. Gastroenterology. 1997; 113: 25–30.

    Article  PubMed  Google Scholar 

  47. Broutet N, Marais A, Lamouliatte H et al. CagA status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia. J Clin Microbiol. 2001; 39: 1319–22.

    Article  PubMed  CAS  Google Scholar 

  48. Lamouliatte H, Samoyeau R, DeMascarel et al. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxicillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther. 1999; 13: 1523–30.

    Article  PubMed  CAS  Google Scholar 

  49. Van Doom L-J, Schneeberger PM, Nouhan N et al. Importance of Helicobacter pylori cag-A and vac-A status for the efficacy of antibiotic treatment. Gut. 2000; 46: 321–6.

    Article  Google Scholar 

  50. Treiber G, Wittig J, Ammon S et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication — a randomized controlled trial (MACLOR STUDY). Arch Intern Med. 2002; 162: 153–60.

    Article  PubMed  CAS  Google Scholar 

  51. Rudi J, Reuter S, Kuck D et al. Relevance of bacterial vac-A genotypes and cag-A status in the efficacy of Helicobacter pylori eradication. Gastroenterology. 1999; 116 (Suppl. 2): A296.

    Google Scholar 

  52. Bochenek W, Tamaoka Y, Osato M et al. Why are cure rates with PPI triple therapy relatively low in the United States? Gastroenterology. 2001; 120 (Suppl. 1): A586.

    Google Scholar 

  53. Go M, Kelly L, Li L et al. CagA and vacA gene polymorphisms in H. pylori from U.S. duodenal ulcer patients and association with eradication. Gastroenterology. 1999; 116 (Suppl. 2): A173.

    Google Scholar 

  54. Yamaoka Y, Ohno T, Sawai N et al. Role of outer membrane proteins oipA, hopO, hopP, and hopZ in colonisation and inflammation: studies in a mouse model. Gut. 2001; 49 (S uppl. 2): A45.

    Google Scholar 

  55. Yamaoka Y, Kikuchi S, El Zimaity H et al. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology. 2002; 123: 414–24.

    Article  PubMed  CAS  Google Scholar 

  56. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet. 2000; 38: 243–70.

    Article  PubMed  CAS  Google Scholar 

  57. Miyoshi M, Mizuno M, Ishiki K et al. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol. 2001; 16: 723–8.

    Article  PubMed  CAS  Google Scholar 

  58. Aoyama N, Tanigawara Y, Kita T et al. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol. 1999; 34 (Suppl. 11): 80–3.

    PubMed  CAS  Google Scholar 

  59. Dojo M, Azuma T, Saito T et al. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis. 2001; 33: 671–5.

    Article  PubMed  CAS  Google Scholar 

  60. Ammon S, Treiber G, Kees F et al. Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2000; 14: 759–66.

    Article  PubMed  CAS  Google Scholar 

  61. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther. 1999; 13: 719–29.

    Article  PubMed  CAS  Google Scholar 

  62. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology. 2000; 118 (Suppl. 1): S2–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. P. Malfertheiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Peitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Treiber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Gastroenterology, McMaster University Medical Centre, 1200 Main Street West, L8N 3Z5, Hamilton, Ontario, Canada

    Richard H. Hunt (Professor of Medicine, Director) (Professor of Medicine, Director)

  2. Department of Gastroenterology and Hepatology, Academic Medical Centre, 9 Meibergdreef, 1105 AZ, Amsterdam, The Netherlands

    Guido N. J. Tytgat (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Malfertheiner, P., Peitz, U., Treiber, G. (2003). What constitutes failure of H. pylori eradication therapy?. In: Hunt, R.H., Tytgat, G.N.J. (eds) Helicobactor pylori. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-1763-2_41

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-1763-2_41

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-5778-5

  • Online ISBN: 978-94-017-1763-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation